ORIGINAL RESEARCH article
Front. Immunol.
Sec. Microbial Immunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1612709
This article is part of the Research TopicTuberculosis and Immune RegulationView all articles
Impact of Cytomegalovirus exposure on Disease Severity, Bacterial burden, Immune Responses and Treatment Outcomes in Tuberculosis
Provisionally accepted- 1National Institutes of Health- NIAID- International Center for Excellence in Research, Chennai, Tamil Nadu, India
- 2National Institute for Research in Tuberculosis (ICMR), Chennai, Tamil Nadu, India
- 3Department of Infectious Diseases, Dignity Health, Chandler, Arizona, United States
- 4Prof. M. Viswanathan Diabetes Research Center, Chennai, Tamil Nadu, India
- 5Regional Medical Research Centre (ICMR), Port Blair, India
- 6University of Massachusetts Medical School, Worcester, Massachusetts, United States
- 7Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIH), Bethesda, Maryland, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Tuberculosis (TB) continues to be one of the leading causes of global mortality. Recent evidence highlights human cytomegalovirus (CMV) as a risk factor for TB. However, the impact of CMV exposure on disease severity, bacterial burden, and TB treatment outcomes remain poorly understood.Methods: Serostatus of CMV was determined by assaying IgG titers in plasma samples by ELISA. Chest X-rays were employed to assess bilateral lung lesions and cavitary diseases, and sputum smear grades to measure bacterial loads in TB subjects. Treatment outcomes were defined as favorable or unfavorable. Cytokine profiles were measured using multiplex ELISA.The study revealed that TB patients with CMV seopositivity had significantly higher bacterial loads (adjusted PR [aPR], 4•14; 95% CI, 2•21-7•16; p<0•001), bilateral lung lesions (aPR, 2•97; 95% CI, 1•71-5•17; P<0•001), cavitary lung lesions (aPR, 4•21; 95% CI, 1•98-6•24; p<0•001) and unfavorable treatment outcomes (aPR, 1•48; 95% CI, 1•08-2•69; p=0•05). Our data also show that TB is associated with significantly lower levels of IFNγ, IL-2, TNFα, IL-1α, and IL-1β but significantly higher levels of IL-10, IFNα, IFNβ, G-CSF, and VEGF in CMV exposed individuals compared to CMV non exposed individuals.Our findings reveal that CMV exposure worsens the severity of TB, increases bacterial burden, and leads to poorer treatment outcomes.. The modulation of cytokine responses in TB patients with CMV exposure suggests a potential mechanism by which CMV may exacerbate TB pathogenesis.
Keywords: Cytomegalovirus, Tuberculosis, Cytokines, Disease Severity, Treatment outcomes
Received: 16 Apr 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 Dasan, Munisankar, Kumar, Abbas, Nancy, Nott, Viswanathan, Shanmugam, Hissar, Thiruvengadam, Kornfeld and Babu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bindu Dasan, National Institutes of Health- NIAID- International Center for Excellence in Research, Chennai, Tamil Nadu, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.